Crohn's Disease Drug Landscape 2026
Approved therapies, pipeline drugs, and clinical trial intelligence
New in 2025-2026
Overview
Crohn's disease is a chronic autoimmune condition and one of two major forms of inflammatory bowel disease (IBD). Affecting over 500,000 Americans, Crohn's can cause inflammation anywhere in the GI tract but most often affects the small intestine, penetrating through all layers of the bowel wall in scattered patches. Treatment has evolved dramatically from corticosteroids to targeted biologics and small molecules. The landscape is now dominated by TNF inhibitors, IL-23 blockers, integrin antagonists, and JAK inhibitors, with emerging targets like TL1A showing promise.
Despite this expanding arsenal, significant unmet need persists: approximately 40% of patients lose response to first-line biologics within two years, and up to 30% require surgery within a decade of diagnosis. Stricturing and fistulizing complications remain poorly managed pharmacologically, driving interest in anti-fibrotic mechanisms such as TL1A inhibition. The treatment paradigm is shifting toward earlier use of advanced therapies, biomarker-guided selection, and combination regimens targeting deeper remission endpoints including mucosal healing. Many therapies are approved for both Crohn's and UC, making the IBD market highly interconnected.
Historical Context
First formally described in 1932 by Dr. Burrill Bernard Crohn and colleagues at Mount Sinai Hospital, who characterized 14 patients with granulomatous inflammation of the terminal ileum. Initially called 'terminal ileitis,' the name was changed to 'regional ileitis' to avoid the impression that the disease was always fatal. Though similar conditions were noted as early as 1769 by Giovanni Morgagni, Crohn's meticulous documentation established it as a distinct clinical entity, correcting the long-held belief that it was a form of intestinal tuberculosis.
Treatment Evolution
Year = first FDA approval for crohn's disease. Dashed = still in clinical development.
Mechanism Landscape
Current crohn's disease treatments span 5 distinct mechanism classes: IL-23 Blocker (3), TNF Blocker (3), Integrin Blocker (2), JAK Inhibitor (1), IL-12/23 Blocker (1). IL-23 Blocker leads with 3 approved drugs.
FDA-Approved Drugs
10 originators + 23 biosimilars10 approved therapies for crohn's disease across 5 mechanism classes: IL-23 Blocker (3), TNF Blocker (3), Integrin Blocker (2), JAK Inhibitor (1), IL-12/23 Blocker (1). Plus 23 biosimilars.
| Drug | Company | Mechanism | Crohn's Disease Approval |
|---|---|---|---|
| OMVOH MIRIKIZUMAB-MRKZ UC | Eli Lilly | IL-23 Blocker | 2025 FDA: 2023 |
| SKYRIZI RISANKIZUMAB-RZAA UC | AbbVie | IL-23 Blocker | 2022 FDA: 2019 |
| RINVOQ UPADACITINIB UC | AbbVie | JAK Inhibitor | 2023 FDA: 2019 |
| TREMFYA GUSELKUMAB UC | Johnson & Johnson | IL-23 Blocker | 2025 FDA: 2017 |
| ENTYVIO VEDOLIZUMAB UC | Takeda | Integrin Blocker | 2014 |
| STELARA USTEKINUMAB UC | Johnson & Johnson | IL-12/23 Blocker | 2016 FDA: 2009 |
| STARJEMZA biosimilar | BIO-THERA SOLUTIONS | IL-12/23 Blocker | 2025 |
| YESINTEK biosimilar | BION BIOLOGICS | IL-12/23 Blocker | 2024 |
| STEQEYMA biosimilar | Celltrion | IL-12/23 Blocker | 2024 |
| IMULDOSA biosimilar | ACRD BIO | IL-12/23 Blocker | 2024 |
| PYZCHIVA biosimilar | Samsung Bioepis | IL-12/23 Blocker | 2024 |
| SELARSDI biosimilar | ALVOTECH USA | IL-12/23 Blocker | 2024 |
| OTULFI biosimilar | Fresenius Kabi | IL-12/23 Blocker | 2024 |
| WEZLANA biosimilar | Amgen | IL-12/23 Blocker | 2023 |
| CIMZIA CERTOLIZUMAB PEGOL | UCB | TNF Blocker | 2008 |
| TYSABRI NATALIZUMAB | Biogen | Integrin Blocker | 2008 FDA: 2004 |
| TYRUKO biosimilar | Novartis | Integrin Blocker | 2023 |
| HUMIRA ADALIMUMAB UC | AbbVie | TNF Blocker | 2007 FDA: 2002 |
| SIMLANDI biosimilar | ALVOTECH USA | TNF Blocker | 2024 |
| YUFLYMA biosimilar | Celltrion | TNF Blocker | 2023 |
| IDACIO biosimilar | Fresenius Kabi | TNF Blocker | 2022 |
| YUSIMRY biosimilar | HERUS BIOSCIENCES | TNF Blocker | 2021 |
| HULIO biosimilar | Viatris | TNF Blocker | 2020 |
| ABRILADA biosimilar | Pfizer | TNF Blocker | 2019 |
| HADLIMA biosimilar | Samsung Bioepis | TNF Blocker | 2019 |
| HYRIMOZ biosimilar | Novartis | TNF Blocker | 2018 |
| CYLTEZO biosimilar | Boehringer Ingelheim | TNF Blocker | 2017 |
| AMJEVITA biosimilar | Amgen | TNF Blocker | 2016 |
| REMICADE INFLIXIMAB UC | Johnson & Johnson | TNF Blocker | 1998 |
| ZYMFENTRA biosimilar | Celltrion | TNF Blocker | 2023 |
| AVSOLA biosimilar | Amgen | TNF Blocker | 2019 |
| RENFLEXIS biosimilar | Samsung Bioepis | TNF Blocker | 2017 |
| INFLECTRA biosimilar | Celltrion | TNF Blocker | 2016 |
23 biosimilars shown inline. Purple = biosimilar of the originator above.
Pipeline Snapshot
Active clinical trials for crohn's disease drugs across all development phases.
Key Companies
Major pharmaceutical companies active in crohn's disease drug development.
Showing top companies by approved drug count and pipeline activity.
Explore Further
Patent & Exclusivity Cliff
Emerging class: TL1A
3 Phase 3 programs targeting TL1A in crohn's disease. No approved drugs in this class yet - first pivotal readouts could reshape the treatment landscape.
Emerging drugs at unvalidated targets
See all emerging drugs →2 drugs in crohn's disease target a molecule with no FDA-approved drug — first-in-class candidates if Phase 3 reads out positive.
Active Phase 3 Trials
10 active Phase 3 programs from US, EU, and Japan-based sponsors across 6 mechanisms: TL1A (3), Interleukin-23 Antagonist (3), IL-23 Blocker (1), Integrin Receptor Antagonist (1), Interleukin-12 Antagonist (1), Janus Kinase Inhibitor (1). Novel classes not yet approved: TL1A, IL-23 Blocker.
| Drug | Sponsor | Trial | Est. Readout |
|---|---|---|---|
| Tulisokibart NEW | Merck | NCT06430801 | 2028-10 |
| Icotrokinra NEW | Johnson & Johnson | NCT07196722 | 2028-09 |
| Duvakitug NEW | Sanofi | NCT07184944 | 2029-08 |
| Afimkibart NEW | Roche | NCT06819891 | 2028-12 |
| Mirikizumab | Eli Lilly | NCT06937099 | 2028-05 |
| Guselkumab | Johnson & Johnson | NCT05347095 | 2027-03 |
| Vedolizumab | Takeda | NCT05442567 | 2033-02 |
| Ustekinumab | Johnson & Johnson | NCT05092269 | 2027-09 |
| Risankizumab | AbbVie | NCT05995353 | 2029-04 |
| Upadacitinib | AbbVie | NCT06332534 | 2027-06 |
Stay Updated
Get notified when we publish new crohn's disease intelligence.
TheraRadar View
2026-04-20Crohn's is the harder half of IBD. Inflammation is patchy and goes through the full thickness of the bowel wall, and can strike anywhere from mouth to anus - and it drives structural damage that existing drugs don't reverse. Roughly 30% of patients require surgery within a decade of diagnosis, ~40% lose response to first-line biologics within two years, and fibrostenotic and fistulizing complications remain poorly managed pharmacologically. The approved classes - TNF, IL-23, integrins, JAKs - all suppress inflammation; none touches the fibrotic cascade that ultimately shapes disease course.
TL1A changes that - it's the first mechanism targeting both the inflammatory cascade and the fibrosis that drives bowel damage. Three programs are in Phase 3 across IBD: Merck's tulisokibart, Roche's afimkibart, and Sanofi's duvakitug, with pivotal readouts expected through 2026-2027. Merck paid $10.8B for Prometheus in 2023 to acquire tulisokibart; that thesis is being validated now. Watch these readouts - they'll reset Crohn's treatment positioning through 2030.